Ileana L PiÃ±a

List of Publications by Year
in descending order

129 papers	13,787 citations	71102 41 h-index	21540 114 g-index
131 all docs	131 docs citations	131 times ranked	12666 citing authors

#	Article	IF	Citations
1	Forecasting the Impact of Heart Failure in the United States. Circulation: Heart Failure, 2013, 6, 606-619.	3.9	2,206
2	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
3	Efficacy and Safety of Exercise Training in Patients With Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1439.	7.4	1,694
4	Exercise and Heart Failure. Circulation, 2003, 107, 1210-1225.	1.6	890
5	Effects of Exercise Training on Health Status in Patients With Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1451.	7.4	631
6	Association of Change in N-Terminal Proâ€“B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2019, 322, 1085.	7.4	403
7	Effect of Natriuretic Peptideâ€“Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2017, 318, 713.	7.4	386
8	Hospital Strategies Associated With 30-Day Readmission Rates for Patients With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 444-450.	2.2	293
9	AACVPR/ACC/AHA 2007 Performance Measures on Cardiac Rehabilitation for Referral to and Delivery of Cardiac Rehabilitation/Secondary Prevention Services. Journal of the American College of Cardiology, 2007, 50, 1400-1433.	2.8	258
10	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 95, 1304-1317.	5.2	232
11	ACC/AHA Clinical Performance Measures for Adults With Chronic Heart Failure. Circulation, 2005, 112, 1853-1887.	1.6	221
12	Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION): Design and rationale. American Heart Journal, 2007, 153, 201-211.	2.7	206
13	Evaluation of the effects of sodiumâ€“glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPERORâ€Preserved Trial. European Journal of Heart Failure, 2019, 21, 1279-1287.	7.1	205
14	Clinical Implications of ChronicÂHeartÂFailure Phenotypes DefinedÂbyÂCluster Analysis. Journal of the American College of Cardiology, 2014, 64, 1765-1774.	2.8	197
15	Heart Failure in Women. Journal of the American College of Cardiology, 2009, 54, 491-498.	2.8	172
16	Cardiac Resynchronization Therapy in Women. JAMA Internal Medicine, 2014, 174, 1340.	5.1	168
17	Variables Measured During Cardiopulmonary Exercise Testing as Predictors of Mortality in Chronic Systolic Heart Failure. Journal of the American College of Cardiology, 2016, 67, 780-789.	2.8	157
18	A controlled trial of cardiac rehabilitation in the home setting using electrocardiographic and voice transtelephonic monitoring. American Heart Journal, 2000, 139, 543-548.	2.7	136

#	Article	IF	Citations
19	Evaluating Quality of Care for Patients With Heart Failure. Circulation, 2000, 101, E122-40.	1.6	130
20	Coronary Computed Tomography AngiographyÂfor the Detection of Cardiac Allograft Vasculopathy. Journal of the American College of Cardiology, 2014, 63, 1992-2004.	2.8	122
21	Utility of Patient-Reported Outcome Instruments in Heart Failure. JACC: Heart Failure, 2016, 4, 165-175.	4.1	120
22	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 1203-1212.	2.2	114
23	Rationale and Design of theÂGUIDE-ITÂStudy. JACC: Heart Failure, 2014, 2, 457-465.	4.1	106
24	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation, 2022, 145, 184-193.	1.6	106
25	Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure. JACC: Heart Failure, 2014, 2, 260-268.	4.1	104
26	Sex differences in heart failure. Clinical Cardiology, 2018, 41, 211-216.	1.8	98
27	Hyperkalemia in Heart Failure. Journal of the American College of Cardiology, 2016, 68, 1575-1589.	2.8	86
28	Sex-Specific Mortality Risk by QRS Morphology and Duration in Patients Receiving CRT. Journal of the American College of Cardiology, 2014, 64, 887-894.	2.8	85
29	The STICH Trial (Surgical Treatment for Ischemic Heart Failure). JACC: Heart Failure, 2013, 1, 400-408.	4.1	82
30	A Randomized Controlled Trial of High-Dose Vitamin D 3 in Patients With Heart Failure. JACC: Heart Failure, 2013, 1, 84-90.	4.1	77
31	Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial. JAMA Cardiology, 2020, 5, 757.	6.1	74
32	Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). American Heart Journal, 2018, 199, 130-136.	2.7	71
33	Natriuretic Peptide Response and Outcomes in Chronic HeartÂFailure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2019, 74, 1205-1217.	2.8	54
34	Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients. Circulation: Heart Failure, 2015, 8, 1044-1051.	3.9	52
35	Frailty Assessment in Advanced Heart Failure. Journal of Cardiac Failure, 2016, 22, 840-844.	1.7	51
36	The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. American Heart Journal, 2014, 167, 193-202.e1.	2.7	50

#	Article	IF	Citations
37	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. Circulation: Heart Failure, 2012, 5, 167-175.	3.9	48
38	Implementation of a Patient Navigator Program to Reduce 30-day Heart Failure Readmission Rate. Progress in Cardiovascular Diseases, 2017, 60, 259-266.	3.1	47
39	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in HeartÂFailure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 127-136.	4.1	47
40	Left Bundle Branch Block Predicts Better Survival in Women Than Men Receiving CardiacÂResynchronization Therapy. JACC: Heart Failure, 2013, 1, 237-244.	4.1	45
41	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 69, 1683-1691.	2.8	45
42	Exercise Capacity and Mortality in Patients With Ischemic Left Ventricular Dysfunction Randomized to Coronary Artery Bypass Graft Surgery or Medical Therapy. JACC: Heart Failure, 2014, 2, 335-343.	4.1	43
43	Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Failure, 2017, 4, 499-506.	3.1	42
44	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Heart Failure, 2022, 24, 143-168.	7.1	41
45	Baseline differences in the HF-ACTION trial by sex. American Heart Journal, 2009, 158, S16-S23.	2.7	40
46	Effects of Exercise Training on Outcomes inÂWomen With Heart Failure. JACC: Heart Failure, 2014, 2, 180-186.	4.1	40
47	Temporal Trends and Factors Associated With Cardiac Rehabilitation Participation Among Medicare Beneficiaries With HeartÂFailure. JACC: Heart Failure, 2021, 9, 471-481.	4.1	38
48	Current challenges for clinical trials of cardiovascular medical devices. International Journal of Cardiology, 2014, 175, 30-37.	1.7	37
49	CABG Improves Outcomes in Patients With Ischemic Cardiomyopathy. JACC: Heart Failure, 2019, 7, 878-887.	4.1	37
50	Clinical factors related to morbidity and mortality in highâ€risk heart failure patients: the GUIDEâ€IT predictive model and risk score. European Journal of Heart Failure, 2019, 21, 770-778.	7.1	36
51	Sleep symptoms and clinical markers of illness in patients with heart failure. Sleep and Breathing, 2005, 9, 127-133.	1.7	35
52	Heart Failure in Women. Clinical Cardiology, 2012, 35, 172-177.	1.8	34
53	Sex Difference in Patients With Ischemic Heart Failure Undergoing Surgical Revascularization. Circulation, 2018, 137, 771-780.	1.6	34
54	Donor Troponin and Survival After Cardiac Transplantation. Circulation: Heart Failure, 2016, 9, .	3.9	33

#	Article	IF	Citations
55	Exercise Training and Pacing Status in Patients With Heart Failure: Results From HF-ACTION. Journal of Cardiac Failure, 2015, 21, 60-67.	1.7	32
56	Frailty Status Modifies the Efficacy of Exercise Training Among Patients With Chronic Heart Failure and Reduced Ejection Fraction: An Analysis From the HF-ACTION Trial. Circulation, 2022, 146, 80-90.	1.6	32
57	Heart Failure Transitions of Care: A Pharmacist-Led Post-Discharge Pilot Experience. Progress in Cardiovascular Diseases, 2017, 60, 249-258.	3.1	30
58	Race, exercise training, and outcomes in chronic heart failure: Findings from Heart Failure - A Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION). American Heart Journal, 2013, 166, 488-495.e1.	2.7	29
59	Relationship Between Galectin-3 Levels and Mineralocorticoid Receptor Antagonist Use in Heart Failure: Analysis From HF-ACTION. Journal of Cardiac Failure, 2014, 20, 38-44.	1.7	28
60	Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e006946.	3.9	28
61	Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 2021, 144, 180-182.	1.6	28
62	Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fractionâ€"Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. American Heart Journal, 2017, 186, 130-138.	2.7	27
63	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	4.1	27
64	Association Between Angiotensin Receptorâ€"Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction. Circulation: Heart Failure, 2021, 14, e008410.	3.9	27
65	Race and Ethnicity in HeartÂFailure. Journal of the American College of Cardiology, 2021, 78, 2589-2598.	2.8	27
66	Trends In Heart Failure Hospitalizations. Current Heart Failure Reports, 2012, 9, 346-353.	3.3	26
67	Exercise and Heart Failure. Chest, 1996, 110, 1317-1327.	0.8	25
68	Sex Differences in Device Therapy for Heart Failure: Utilization, Outcomes, and Adverse Events. Journal of Women's Health, 2015, 24, 261-271.	3.3	25
69	Non-invasive assessment of low risk acute chest pain in the emergency department: A comparative meta-analysis of prospective studies. International Journal of Cardiology, 2015, 187, 565-580.	1.7	24
70	Tolerability of extended duration intravenous milrinone in patients hospitalized for advanced heart failure and the usefulness of uptitration of oral angiotensin-converting enzyme inhibitors. American Journal of Cardiology, 1999, 84, 894-899.	1.6	23
71	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. Journal of Cardiac Failure, 2022, 28, 1063-1077.	1.7	23
72	Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities â€" a National Heart, Lung, and Blood Institute workshop report. BMC Proceedings, 2017, 11, 11.	1.6	22

#	Article	IF	Citations
73	Sexâ€based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. European Journal of Heart Failure, 2020, 22, 2018-2025.	7.1	21
74	Economic and Quality-of-Life Outcomes of Natriuretic Peptideâ€“Guided Therapy for HeartÂFailure. Journal of the American College of Cardiology, 2018, 72, 2551-2562.	2.8	20
75	Stress-Induced Cardiomyopathy. Heart Failure Clinics, 2019, 15, 41-53.	2.1	18
76	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. Circulation: Heart Failure, 2020, 13, e007829.	3.9	18
77	Heart Failure in Women. Cardiology in Review, 2003, 11, 337-344.	1.4	17
78	The Potential Role of Natriuretic Peptideâ€“Guided Management for Patients Hospitalized for Heart Failure. Journal of Cardiac Failure, 2015, 21, 233-239.	1.7	16
79	Microvascular obstruction detected by cardiac MRI after AMI for the prediction of LV remodeling and MACE: A meta-analysis of prospective trials. International Journal of Cardiology, 2016, 202, 344-348.	1.7	16
80	Heart Failure Postdischarge Clinic: A Pharmacist-led Approach to Reduce Readmissions. Current Problems in Cardiology, 2019, 44, 100407.	2.4	15
81	Cardiovascular Disease in Women. Cardiology in Review, 2011, 19, 71-75.	1.4	14
82	Authorship in a multicenter clinical trial: The Heart Failureâ€”A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) Scoring System Results. American Heart Journal, 2015, 169, 457-463.e6.	2.7	13
83	Cardiac Rehabilitation in Heart Failure: A Brief Review and Recommendations. Current Cardiology Reports, 2010, 12, 223-229.	2.9	12
84	From Acute Decompensated to Chronic Heart Failure. American Journal of Cardiology, 2014, 114, 1923-1929.	1.6	12
85	Burden of medical coâ€morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. European Journal of Heart Failure, 2019, 21, 373-381.	7.1	12
86	Participation in a Heart Failure Clinical Trial. Circulation: Heart Failure, 2021, 14, e008242.	3.9	12
87	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). American Journal of Cardiology, 2016, 118, 1211-1216.	1.6	11
88	Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials. Europace, 2018, 20, f211-f216.	1.7	11
89	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. European Journal of Preventive Cardiology, 2022, 29, 275-300.	1.8	11
90	Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. Circulation: Heart Failure, 2015, 8, 709-716.	3.9	9

#	Article	IF	Citations
91	Statins and Exercise Training Response inÂHeart Failure Patients. JACC: Heart Failure, 2016, 4, 617-624.	4.1	9
92	Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fractionâ€"Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. American Heart Journal, 2018, 199, 97-104.	2.7	9
93	Persistence of 123I-mIBG Prognostic Capability in Relation to Medical Therapy in Heart Failure (from) Tj ETQq1 1 0.784314 rgBT /Over	1.6	8
94	The American Heart Association Heart Failure Summit, Bethesda, April 12, 2017. Circulation: Heart Failure, 2018, 11, e004957.	3.9	8
95	Quality Improvement in Heart Failure: A Randomized Educational Intervention to Change Provider Behavior. Congestive Heart Failure, 2012, 18, 245-253.	2.0	7
96	Atrial fibrillation inducibility during cavo-tricuspid isthmus dependent atrial flutter ablation for the prediction of clinical atrial fibrillation. International Journal of Cardiology, 2017, 240, 246-250.	1.7	7
97	Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation, 2022, 145, 819-828.	1.6	7
98	Government continues to have an important role in promoting cardiovascular health. American Heart Journal, 2018, 198, 160-165.	2.7	6
99	Differences in NTâ€proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association, 2021, 10, e019712.	3.7	6
100	Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction. American Journal of Cardiology, 2018, 122, 999-1007.	1.6	5
101	Managing the Economic Challenges in the Treatment of Heart Failure. Progress in Cardiovascular Diseases, 2018, 61, 476-483.	3.1	4
102	Effect of patiromer on serum potassium in hyperkalemic patients with heart failure: Pooled analysis of 3 randomized trials. Progress in Cardiovascular Diseases, 2020, 63, 656-661.	3.1	4
103	Managing the economic challenges in the treatment of heart failure. BMC Cardiovascular Disorders, 2021, 21, 612.	1.7	4
104	Improving Provider Adherence to Guideline Recommendations in Heart Failure. Current Heart Failure Reports, 2018, 15, 350-356.	3.3	3
105	SGLT2 inhibitors: the story continues to unfold. European Heart Journal, 2021, , .	2.2	3
106	The influence of comorbidities on achieving an Nâ€terminal proâ€bâ€type natriuretic peptide target: a secondary analysis of the GUIDEâ€IT trial. ESC Heart Failure, 2021, , .	3.1	3
107	Disparities in Women with Heart Failure. Current Cardiovascular Risk Reports, 2011, 5, 261-265.	2.0	2
108	Improving Quality of Cardiac Care: A Global Mandate. Revista Espanola De Cardiologia (English Ed), 2015, 68, 924-927.	0.6	2

#	Article	IF	Citations
109	Greater Pain Severity Is Associated with Worse Outcomes in Patients with Heart Failure. Journal of Cardiovascular Translational Research, 2021, 14, 984-991.	2.4	2
110	Do PRO Measures Function the Same Way for all Individuals With Heart Failure?. Journal of Cardiac Failure, 2023, 29, 210-216.	1.7	2
111	The AHF SCENE II Preceptorship Program: Rationale and Design of an Educational Program to Optimize Management of Advanced Heart Failure. Congestive Heart Failure, 2000, 6, 319-324.	2.0	1
112	Behavioral Intervention, Nutrition, and Exercise Trials in Heart Failure. Heart Failure Clinics, 2011, 7, 467-479.	2.1	1
113	If It Is Not Health Care Access or Insurance Coverage, Then Why Do RacialÂDisparities Persist?. JACC: Heart Failure, 2018, 6, 421-423.	4.1	1
114	Sex Differences in Heart Failureâ€"Female Representation in Heart Failure Studies. Current Cardiovascular Risk Reports, 2019, 13, 1.	2.0	1
115	Policy and Payment Challenges in the Postpandemic Treatment of Heart Failure: Value-Based Care and Telehealth. Journal of Cardiac Failure, 2022, 28, 835-844.	1.7	1
116	Assessing race and ethnicity differences in outcomes based on GDMT and target NT-proBNP in patients with heart failure with reduced ejection fraction: An analysis of the GUIDE-IT study. Progress in Cardiovascular Diseases, 2022, , .	3.1	1
117	Criteria for use of intravenous milrinone in adult inpatients. American Journal of Health-System Pharmacy, 1995, 52, 1918-1919.	1.0	0
118	Transitions of Care in Heart Failure: The Case for Comparative Effectiveness Research. Current Heart Failure Reports, 2011, 8, 81-83.	3.3	0
119	Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction in Women. Archives of Internal Medicine, 2011, 171, 1088-9.	3.8	0
120	Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004643.	2.2	0
121	The New Kids on the Block: Don't Delay. Journal of Cardiac Failure, 2020, 26, 811-812.	1.7	0
122	One Small Step . . .. JACC: CardioOncology, 2020, 2, 596-598.	4.0	0
123	Acute Kidney Injury: To Be or Not to Be: That Is the Question: Itâ€™s the Company It Keeps. American Journal of Nephrology, 2020, 51, 169-171.	3.1	0
124	A â€œSilentâ€•Passenger Speaks Loudly. JACC: Heart Failure, 2020, 8, 289-290.	4.1	0
125	How Long Will We Play the Ostrich Game?. Circulation: Heart Failure, 2020, 13, e007043.	3.9	0
126	Abstract P320: Discordance of Framingham Risk Score and Reynolds Risk Score to Global Vascular Risk Score: Results from the Hispanic Community Health Study/Study of Latinos. Circulation, 2014, 129, .	1.6	0

#	Article	IF	Citations
127	Heart Failure Management and Development of Heart Failure Programs. , 2017, , 783-803.		0
128	Impedance Cardiography. , 0, , 77-87.		0
129	Time to Re-Examine Maternity Leave in Cardiology Training. Journal of the American College of Cardiology, 2022, 79, 2127-2128.	2.8	0